Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL.

J Virol. 2013 Feb;87(3):1544-53. doi: 10.1128/JVI.02294-12. Epub 2012 Nov 14.

2.

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

Schneider MD, Sarrazin C.

Antiviral Res. 2014 May;105:64-71. doi: 10.1016/j.antiviral.2014.02.011. Epub 2014 Feb 25.

PMID:
24583028
3.

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.

Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F.

Virol J. 2013 Dec 17;10:355. doi: 10.1186/1743-422X-10-355.

4.

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G.

PLoS One. 2012;7(4):e34372. doi: 10.1371/journal.pone.0034372. Epub 2012 Apr 12.

5.

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.

Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL.

Antimicrob Agents Chemother. 2013 Dec;57(12):6236-45. doi: 10.1128/AAC.01578-13. Epub 2013 Oct 7.

6.

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G.

Hepatology. 2012 Dec;56(6):2106-15. doi: 10.1002/hep.25962.

PMID:
22806681
7.

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL.

Clin Infect Dis. 2013 Jul;57(2):221-9. doi: 10.1093/cid/cit226. Epub 2013 Apr 10.

8.

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.

Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Nájera I.

J Antimicrob Chemother. 2008 Jun;61(6):1205-16. doi: 10.1093/jac/dkn085. Epub 2008 Mar 13.

9.

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.

Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C.

PLoS One. 2015 Aug 28;10(8):e0134395. doi: 10.1371/journal.pone.0134395. eCollection 2015.

10.

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Halfon P, Sarrazin C.

Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x. Review.

PMID:
22212577
11.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.

J Clin Virol. 2012 Aug;54(4):352-4. doi: 10.1016/j.jcv.2012.04.024. Epub 2012 Jun 1.

PMID:
22658798
12.

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.

Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C.

J Clin Virol. 2011 Dec;52(4):321-7. doi: 10.1016/j.jcv.2011.08.015. Epub 2011 Sep 15.

PMID:
21924672
13.

Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.

Margeridon-Thermet S, Le Pogam S, Li L, Liu TF, Shulman N, Shafer RW, Najera I.

PLoS One. 2014 Aug 20;9(8):e105569. doi: 10.1371/journal.pone.0105569. eCollection 2014.

14.

Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.

Sede MM, Laufer NL, Quarleri J.

Int J Antimicrob Agents. 2015 Aug;46(2):219-24. doi: 10.1016/j.ijantimicag.2015.04.011. Epub 2015 Jun 4.

PMID:
26100213
15.

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S.

Hepatology. 2007 Sep;46(3):631-9.

PMID:
17680654
16.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

17.

Antiviral resistance and direct-acting antiviral agents for HCV.

Aloia AL, Locarnini S, Beard MR.

Antivir Ther. 2012;17(6 Pt B):1147-62. doi: 10.3851/IMP2426. Epub 2012 Oct 5. Review.

PMID:
23188771
18.

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H.

J Hepatol. 2013 Apr;58(4):646-54. doi: 10.1016/j.jhep.2012.11.012. Epub 2012 Nov 22.

PMID:
23178977
19.

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.

Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P.

J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29.

20.

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.

J Infect Dis. 2008 Sep 15;198(6):800-7. doi: 10.1086/591141.

Items per page

Supplemental Content

Write to the Help Desk